Proteomic Analysis of Biomarkers Predicting Treatment Response in Patients with Head and Neck Cancers

Head and neck cancers (HNCs) are the sixth most commonly diagnosed cancer and the eighth leading cause of cancer-related mortality worldwide, with squamous cell carcinoma being the most prevalent type. The global incidence of HNCs is steadily increasing, projected to rise by approximately 30% per year by 2030, a trend observed in both developed and undeveloped countries. This study involved serum proteomic profiling to identify predictive clinical biomarkers in cancer patients undergoing chemoradiotherapy (CRT). Fifteen HNC patients at Tikur Anbessa Specialized Hospital, Radiotherapy (RT) center in Addis Ababa were enrolled. Serum samples were collected before and after RT, and patients were classified as responders (R) or non-responders (NR). Protein concentrations in the serum were determined using the Bradford assay, followed by nano-HPLC-MS/MS for protein profiling. Progenesis QI for proteomics identified 55 differentially expressed proteins (DEPs) between R and NR, with a significance of <i>p</i> < 0.05 and a fold-change (FC) ≥ 1.5. The top five-up-regulated proteins included <i>MAD1L1</i>, <i>PSMC2</i>, <i>TRIM29</i>, <i>C5</i>, and <i>SERPING1</i>, while the top five-down-regulated proteins were <i>RYR1</i>, <i>HEY2</i>, <i>HIF1A</i>, <i>TF</i>, and <i>CNN3</i>. Notably, about 16.4% of the DEPs were involved in cellular responses to DNA damage from cancer treatments, encompassing proteins related to deoxyribonucleic acid (DNA) damage sensing, checkpoint activation, DNA repair, and apoptosis/cell cycle regulation. The analysis of the relative abundance of ten proteins with high confidence scores identified three DEPs: <i>ADIPOQ</i>, <i>HEY2</i>, and <i>FUT10</i> as potential predictive biomarkers for treatment response. This study highlighted the identification of three potential predictive biomarkers-<i>ADIPOQ</i>, <i>HEY2</i>, and <i>FUT10</i>-through serum proteomic profiling in HNC patients undergoing RT, emphasizing their significance in predicting treatment response.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2024-11-21
DOI
https://doi.org/10.3390/ijms252312513
Citations
10
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
5.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Proteomic Analysis of Biomarkers Predicting Treatment Response in Patients with Head and Neck Cancers

Rita Lombardi, Biagio Pucci, Alfredo Budillon, Elena Di Gennaro et al.
10 citations
International Journal of Molecular Sciences
Head and Neck Cancer Studies
5.80
article

Proteomic Analysis of Biomarkers Predicting Treatment Response in Patients with Head and Neck Cancers

Rita Lombardi, Biagio Pucci, Alfredo Budillon, Elena Di Gennaro, Gurja Belay, Heluf Medhin, Edom Seife, Emeshaw Damtew Zebene
article en
10 citations

Abstract

Head and neck cancers (HNCs) are the sixth most commonly diagnosed cancer and the eighth leading cause of cancer-related mortality worldwide, with squamous cell carcinoma being the most prevalent type. The global incidence of HNCs is steadily increasing, projected to rise by approximately 30% per year by 2030, a trend observed in both developed and undeveloped countries. This study involved serum proteomic profiling to identify predictive clinical biomarkers in cancer patients undergoing chemoradiotherapy (CRT). Fifteen HNC patients at Tikur Anbessa Specialized Hospital, Radiotherapy (RT) center in Addis Ababa were enrolled. Serum samples were collected before and after RT, and patients were classified as responders (R) or non-responders (NR). Protein concentrations in the serum were determined using the Bradford assay, followed by nano-HPLC-MS/MS for protein profiling. Progenesis QI for proteomics identified 55 differentially expressed proteins (DEPs) between R and NR, with a significance of <i>p</i> < 0.05 and a fold-change (FC) ≥ 1.5. The top five-up-regulated proteins included <i>MAD1L1</i>, <i>PSMC2</i>, <i>TRIM29</i>, <i>C5</i>, and <i>SERPING1</i>, while the top five-down-regulated proteins were <i>RYR1</i>, <i>HEY2</i>, <i>HIF1A</i>, <i>TF</i>, and <i>CNN3</i>. Notably, about 16.4% of the DEPs were involved in cellular responses to DNA damage from cancer treatments, encompassing proteins related to deoxyribonucleic acid (DNA) damage sensing, checkpoint activation, DNA repair, and apoptosis/cell cycle regulation. The analysis of the relative abundance of ten proteins with high confidence scores identified three DEPs: <i>ADIPOQ</i>, <i>HEY2</i>, and <i>FUT10</i> as potential predictive biomarkers for treatment response. This study highlighted the identification of three potential predictive biomarkers-<i>ADIPOQ</i>, <i>HEY2</i>, and <i>FUT10</i>-through serum proteomic profiling in HNC patients undergoing RT, emphasizing their significance in predicting treatment response.

International Journal of Molecular SciencesVol. 25(23)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Addis Ababa University (ET)
International Atomic Energy Agency, Addis Ababa University
Good health and well-being
Openalex Percentile: Top 3%
Head and Neck Cancer Studies
5.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.